WAVE Life Sciences (NASDAQ:WVE) Announces Earnings Results, Beats Expectations By $0.03 EPS

WAVE Life Sciences (NASDAQ:WVE) released its earnings results on Tuesday. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.03, FiscalAI reports. The firm had revenue of $13.16 million during the quarter, compared to the consensus estimate of $4.51 million.

Here are the key takeaways from WAVE Life Sciences’ conference call:

• WVE-007 obesity program advanced with Phase IIa monotherapy and tirzepatide-combination trials underway, while a post-incretin maintenance study remains on track to begin in Q4 2026. Management expects higher-baseline-adiposity patients and multiple dosing to support progress toward the 5% one-year weight-loss regulatory benchmark.
• The company reported encouraging clinical durability and body-composition findings for WVE-007, including reductions in visceral and total fat with lean-mass preservation, and expects additional 600 mg Phase I data in Q4 to inform potency, duration, safety, and dosing frequency.
• FDA discussions supported a potentially efficient single two-year registrational trial for WVE-006 in AATD, with a one-year interim analysis that could support accelerated approval based on biomarkers. The company also said the FDA was comfortable with its LC-MS assay for measuring M-AAT and Z-AAT.
• Wave plans to submit a CTA for its second RNA-editing candidate, WVE-008 for PNPLA3 I148M liver disease, in 2026 and intends to use pre-genotyped populations to accelerate first-in-human enrollment.
• Operating expenses and net loss increased year over year as Wave invested in its expanding clinical pipeline; third-quarter net loss was $61.9 million versus $53.9 million a year earlier. The company ended the quarter with $431 million in cash and securities, projected to fund operations into Q3 2028, plus a $12 million GSK milestone expected in Q4.

WAVE Life Sciences Stock Performance

WAVE Life Sciences stock opened at $3.45 on Wednesday. The company’s 50-day moving average is $4.17 and its 200-day moving average is $7.65. WAVE Life Sciences has a fifty-two week low of $3.04 and a fifty-two week high of $21.73.

Key Headlines Impacting WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: WAVE reported a third-quarter loss of $0.30 per share, narrowing the expected loss of $0.33–$0.34. Revenue of $13.16 million also substantially exceeded the approximately $4.51 million consensus estimate, providing the primary near-term catalyst for the stock. Wave Life Sciences Q3 earnings report
• Positive Sentiment: The company said planning is underway for a registrational trial of WVE-006 in alpha-1 antitrypsin deficiency (AATD). An interim biomarker analysis could potentially support an accelerated-approval pathway, strengthening investor expectations for a significant clinical catalyst. WAVE Life Sciences third-quarter business update
• Positive Sentiment: Management discussed the results and development plans during the third-quarter earnings call, giving investors additional detail on WVE-006 and the broader pipeline. WAVE Life Sciences Q3 2026 earnings call transcript

Insider Transactions at WAVE Life Sciences

In other WAVE Life Sciences news, Director Heidi Wagner sold 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $6.01, for a total transaction of $42,070.00. Following the transaction, the director owned 44,930 shares of the company’s stock, valued at $270,029.30. The trade was a 13.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Adrian Rawcliffe sold 12,700 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $5.29, for a total value of $67,183.00. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 23,564 shares of company stock worth $132,476. 24.34% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on WVE shares. Citigroup decreased their price target on shares of WAVE Life Sciences from $24.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, July 31st. UBS Group began coverage on shares of WAVE Life Sciences in a report on Thursday, October 15th. They set a “buy” rating and a $11.00 target price for the company. Mizuho decreased their target price on shares of WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating for the company in a research report on Tuesday, August 4th. Zacks Research lowered shares of WAVE Life Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of WAVE Life Sciences in a research report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $20.89.

WAVE Life Sciences Company Profile

WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.